Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hansa Biopharma AB ( (SE:HNSA) ) has shared an update.
Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer, effective July 14, 2025. Dr. Philipson brings over 25 years of experience in drug development, particularly in rare diseases and gene therapy, and will play a crucial role in advancing Hansa’s development programs and regulatory submissions. His expertise is expected to enhance the company’s strategic development plans and strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 223,266
Current Market Cap: SEK2.38B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.